30 related articles for article (PubMed ID: 7710439)
1. Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.
Sharma S; Lee J; Zhou J; Steele VE
Cancer Prev Res (Phila); 2011 Aug; 4(8):1233-42. PubMed ID: 21562034
[TBL] [Abstract][Full Text] [Related]
2. Licofelone: the answer to unmet needs in osteoarthritis therapy?
Kulkarni SK; Singh VP
Curr Rheumatol Rep; 2008 Jan; 10(1):43-8. PubMed ID: 18457611
[TBL] [Abstract][Full Text] [Related]
3. Activity and potential role of licofelone in the management of osteoarthritis.
Cicero AF; Laghi L
Clin Interv Aging; 2007; 2(1):73-9. PubMed ID: 18044077
[TBL] [Abstract][Full Text] [Related]
4. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone.
Cicero AF; Derosa G; Gaddi A
Drugs Aging; 2005; 22(5):393-403. PubMed ID: 15903352
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.
Smolka AJ; Goldenring JR; Gupta S; Hammond CE
BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114
[TBL] [Abstract][Full Text] [Related]
6. [On the pharmacology of 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol (WA 335), a histamine and serotonin antagonist (author's transl)].
Engelhardt G
Arzneimittelforschung; 1975 Nov; 25(11):1723-37. PubMed ID: 1049
[TBL] [Abstract][Full Text] [Related]
7. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
11. General pharmacological properties of the main metabolite of flosequinan.
Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
[TBL] [Abstract][Full Text] [Related]
12. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.
Algate DR; Augustin J; Atterson PR; Beard DJ; Jobling CM; Laufer S; Munt PL; Tries S
Arzneimittelforschung; 1995 Feb; 45(2):159-65. PubMed ID: 7710439
[TBL] [Abstract][Full Text] [Related]
13. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
